SciSparc (NASDAQ:SPRC) Issues Earnings Results

SciSparc (NASDAQ:SPRC) released its quarterly earnings data on Wednesday. The company reported ($4.85) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.14 million for the quarter.

SciSparc Trading Up 1.1%

Shares of SPRC stock traded up $0.05 during mid-day trading on Wednesday, hitting $4.75. 12,185 shares of the stock were exchanged, compared to its average volume of 480,269. SciSparc has a 52-week low of $2.98 and a 52-week high of $54.63. The firm has a fifty day moving average of $5.94 and a 200 day moving average of $5.83.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SPRC shares. Wall Street Zen raised SciSparc to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a research report on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About SciSparc

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies that combine cannabinoids with other pharmaceutical compounds. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including neurological and central nervous system disorders.

SciSparc has developed a pipeline that has included SCI-110, an investigational cannabinoid-based treatment being studied for conditions such as Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210, a combination therapy under development for autism spectrum disorder.